A detailed history of Tocqueville Asset Management L.P. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Tocqueville Asset Management L.P. holds 95,239 shares of BMY stock, worth $5.55 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
95,239
Previous 120,462 20.94%
Holding current value
$5.55 Million
Previous $5 Million 1.48%
% of portfolio
0.08%
Previous 0.08%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$39.66 - $51.75 $1 Million - $1.31 Million
-25,223 Reduced 20.94%
95,239 $4.93 Million
Q2 2024

Aug 12, 2024

SELL
$40.25 - $52.99 $36,386 - $47,902
-904 Reduced 0.74%
120,462 $5 Million
Q1 2024

May 09, 2024

SELL
$47.98 - $54.4 $13,194 - $14,960
-275 Reduced 0.23%
121,366 $6.58 Million
Q4 2023

Feb 12, 2024

SELL
$48.48 - $57.85 $13.2 Million - $15.7 Million
-272,000 Reduced 69.1%
121,641 $6.24 Million
Q3 2023

Nov 09, 2023

SELL
$57.89 - $64.73 $91,929 - $102,791
-1,588 Reduced 0.4%
393,641 $22.8 Million
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $142,965 - $158,740
-2,244 Reduced 0.56%
395,229 $25.3 Million
Q1 2023

May 10, 2023

BUY
$65.71 - $74.53 $981,707 - $1.11 Million
14,940 Added 3.91%
397,473 $27.5 Million
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $56,975 - $67,466
832 Added 0.22%
382,533 $27.5 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $103 - $61,395
-799 Reduced 0.21%
381,701 $27.1 Million
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $1.46 Million - $1.61 Million
20,146 Added 5.56%
382,500 $29.5 Million
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $351,112 - $421,014
-5,711 Reduced 1.55%
362,354 $26.5 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $47,677 - $55,580
-889 Reduced 0.24%
368,065 $22.9 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $37,987 - $44,497
-642 Reduced 0.17%
368,954 $21.8 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $1.38 Million - $1.5 Million
-22,234 Reduced 5.67%
369,596 $24.7 Million
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $294,207 - $330,896
-4,958 Reduced 1.25%
391,830 $24.7 Million
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $42,034 - $47,633
728 Added 0.18%
396,788 $24.6 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $1.26 Million - $1.39 Million
-21,864 Reduced 5.23%
396,060 $23.9 Million
Q2 2020

Aug 12, 2020

SELL
$54.82 - $64.09 $934,297 - $1.09 Million
-17,043 Reduced 3.92%
417,924 $24.6 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $638,139 - $927,364
-13,753 Reduced 3.06%
434,967 $24.2 Million
Q4 2019

Jan 14, 2020

BUY
$49.21 - $64.19 $1.46 Million - $1.91 Million
29,738 Added 7.1%
448,720 $28.8 Million
Q3 2019

Oct 31, 2019

SELL
$42.77 - $50.71 $286,559 - $339,757
-6,700 Reduced 1.57%
418,982 $21.2 Million
Q2 2019

Jul 31, 2019

BUY
$44.62 - $49.34 $11.1 Million - $12.2 Million
247,675 Added 139.14%
425,682 $19.3 Million
Q1 2019

Apr 30, 2019

BUY
$45.12 - $53.8 $274,780 - $327,642
6,090 Added 3.54%
178,007 $8.49 Million
Q4 2018

Feb 08, 2019

SELL
$48.76 - $63.23 $18.8 Million - $24.4 Million
-385,821 Reduced 69.18%
171,917 $8.94 Million
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $5.06 Million - $5.71 Million
-91,668 Reduced 14.12%
557,738 $34.6 Million
Q2 2018

Aug 13, 2018

SELL
$50.53 - $62.98 $155,632 - $193,978
-3,080 Reduced 0.47%
649,406 $35.9 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $568,101 - $653,999
-9,481 Reduced 1.43%
652,486 $41.3 Million
Q4 2017

Feb 13, 2018

SELL
$59.94 - $65.35 $51,248 - $55,874
-855 Reduced 0.13%
661,967 $40.6 Million
Q3 2017

Oct 30, 2017

BUY
$55.23 - $63.74 $36.6 Million - $42.2 Million
662,822
662,822 $42.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Tocqueville Asset Management L.P. Portfolio

Follow Tocqueville Asset Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Tocqueville Asset Management L.P. with notifications on news.